Xeris Biopharma Holdings (XERS): SEC Form 3 filed by new insider Taddese Menassie
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
New director Taddese Menassie filed initial Form 3 disclosing no beneficially owned securities at Xeris Biopharma.
Historical context for XERS
Across the 23 sessions after earlier XERS headlines, the stock closed higher 13 times and lower 10 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | XERS | SPY |
|---|---|---|---|
| Nov 2, 2026 | Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors | -5.0% | -0.5% |
| Oct 22, 2026 | Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 | +0.7% | -1.2% |
| Oct 15, 2026 | Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings | +3.1% | +0.3% |
| Oct 5, 2026 | Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | +11.6% | +0.7% |
| Sep 9, 2026 | Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism | -9.1% | -0.5% |
| Aug 26, 2026 | Xeris Announces Details for XP-8121 Program Overview Webinar | -0.7% | +0.0% |
Quantisnow market dataNASDAQ
XERS
Xeris Biopharma Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for XERS
Full XERS profile on Quantisnow Follow XERS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time